Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
T Tozuka, R Noro, A Miyanaga, S Nakamichi… - Cancer …, 2023 - Wiley Online Library
Background The epidermal growth factor receptor (EGFR) mutation is a risk factor
associated with brain metastases (BMs) in patients with non‐small cell lung cancer …
associated with brain metastases (BMs) in patients with non‐small cell lung cancer …
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
T Tozuka, R Noro, H Mizutani, F Kurimoto, T Hakozaki… - Lung Cancer, 2024 - Elsevier
Objectives Osimertinib is a standard treatment for patients with EGFR-mutant non-small cell
lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is …
lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is …
1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS …
Background Central nervous system (CNS) metastases are common among patients with
epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer …
epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer …
Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
Y Inutsuka, E Iwama, Y Shiraishi, Y Yoneshima… - Respiratory …, 2024 - Elsevier
Background Osimertinib shows pronounced efficacy for EGFR mutation–positive non–small
cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases …
cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases …
Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
IM Goldstein, LC Roisman… - Neuro-Oncology …, 2020 - academic.oup.com
Background Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier …
kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier …
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis …
Y Zhou, B Wang, J Qu, F Yu, Y Zhao, S Li, Y Zeng… - Lung Cancer, 2020 - Elsevier
Objectives Central nervous system (CNS) metastases are common complications in
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) …
Osimertinib for EGFR‐Mutant Lung Cancer with Brain Metastases: Results from a Single‐Center Retrospective Study
Introduction Osimertinib is a third‐generation tyrosine kinase inhibitor, initially approved for
epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with …
epidermal growth factor receptor (EGFR) mutant non‐small cell lung cancer (NSCLC) with …
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer
C Hui, V Qu, JY Wang, R von Eyben, YC Chang… - Journal of Neuro …, 2022 - Springer
Purpose Although osimertinib has excellent intracranial activity in metastatic non-small cell
lung cancer (NSCLC) with exon 19 deletion or L858R EGFR alterations, measures of local …
lung cancer (NSCLC) with exon 19 deletion or L858R EGFR alterations, measures of local …
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: Treatment rationale and protocol design of the …
K Wakuda, H Yamaguchi, H Kenmotsu, M Fukuda… - BMC cancer, 2020 - Springer
Background Patients with activating epidermal growth factor receptor (EGFR) mutations are
highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported …
highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported …
Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor …
L Zhang, Y You, X Liu, F Liu, K Nie, Y Ji - Thoracic Cancer, 2023 - Wiley Online Library
Background The efficacy and safety of osimertinib combined with bevacizumab in non‐small
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …